EA201591510A1 - Фармацевтическая препаративная форма, содержащая фосфатидилхолин, применяемая для лечения язвенного колита - Google Patents

Фармацевтическая препаративная форма, содержащая фосфатидилхолин, применяемая для лечения язвенного колита

Info

Publication number
EA201591510A1
EA201591510A1 EA201591510A EA201591510A EA201591510A1 EA 201591510 A1 EA201591510 A1 EA 201591510A1 EA 201591510 A EA201591510 A EA 201591510A EA 201591510 A EA201591510 A EA 201591510A EA 201591510 A1 EA201591510 A1 EA 201591510A1
Authority
EA
Eurasian Patent Office
Prior art keywords
acid
treatment
phosphatidylholin
applicable
form containing
Prior art date
Application number
EA201591510A
Other languages
English (en)
Other versions
EA029514B1 (ru
Inventor
Герхард Кайльхауер
Original Assignee
Липид Терапойтикс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Липид Терапойтикс Гмбх filed Critical Липид Терапойтикс Гмбх
Publication of EA201591510A1 publication Critical patent/EA201591510A1/ru
Publication of EA029514B1 publication Critical patent/EA029514B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Фармацевтическая препаративная форма, содержащая фосфатидилхолиновый продукт формулы (I), отличающаяся тем, что Rпредставляет собой радикал насыщенной или ненасыщенной жирной кислоты с 12-24 атомами углерода и Rпредставляет собой радикал насыщенной или ненасыщенной жирной кислоты с 12-24 атомами углерода, где фосфатидилхолиновый продукт содержит следующие количества жирных кислот, мас.%: 55-72 линолевой кислоты; 10-18 пальмитиновой кислоты; 7-15 масляной кислоты; 2-8 линоленовой кислоты; 2-8 стеариновой кислоты и по меньшей мере одно фармацевтически приемлемое вспомогательное вещество для замедленного высвобождения, может быть использована для усовершенствованного лечения язвенного колита.
EA201591510A 2013-03-26 2014-03-25 Фармацевтическая препаративная форма, содержащая фосфатидилхолин, применяемая для лечения язвенного колита EA029514B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13161089 2013-03-26
PCT/EP2014/055947 WO2014154683A1 (en) 2013-03-26 2014-03-25 Pharmaceutical formulation comprising phosphatidylcholine for the treatment of ulcerative colitis

Publications (2)

Publication Number Publication Date
EA201591510A1 true EA201591510A1 (ru) 2016-01-29
EA029514B1 EA029514B1 (ru) 2018-04-30

Family

ID=47913311

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591510A EA029514B1 (ru) 2013-03-26 2014-03-25 Фармацевтическая препаративная форма, содержащая фосфатидилхолин, применяемая для лечения язвенного колита

Country Status (26)

Country Link
US (1) US20160045523A1 (ru)
EP (1) EP2978416B1 (ru)
JP (1) JP6262843B2 (ru)
KR (1) KR20150132841A (ru)
CN (1) CN105377247B (ru)
AU (1) AU2014243102B2 (ru)
BR (1) BR112015023849A2 (ru)
CA (1) CA2907401A1 (ru)
CL (1) CL2015002832A1 (ru)
DK (1) DK2978416T3 (ru)
EA (1) EA029514B1 (ru)
ES (1) ES2605650T3 (ru)
HK (1) HK1217089A1 (ru)
HU (1) HUE030707T2 (ru)
IL (1) IL241019A0 (ru)
LT (1) LT2978416T (ru)
MD (1) MD20150089A2 (ru)
MX (1) MX2015013511A (ru)
PE (1) PE20160037A1 (ru)
PH (1) PH12015502199A1 (ru)
PL (1) PL2978416T3 (ru)
PT (1) PT2978416T (ru)
SG (1) SG11201507777TA (ru)
UA (1) UA115585C2 (ru)
WO (1) WO2014154683A1 (ru)
ZA (1) ZA201507910B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5715070B2 (ja) 2009-02-16 2015-05-07 ノグラ ファーマ リミテッド アルキルアミド化合物およびその使用
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
US20190046490A1 (en) * 2016-02-26 2019-02-14 Nogra Pharma Limited Methods of treating lactose intolerance
BR112021015609A2 (pt) 2019-02-08 2021-10-05 Nogra Pharma Limited Processo de fabricação de ácido 3-(4?-aminofenil)-2-metoxipropiônico, e análogos e intermediários do mesmo
US20220162238A1 (en) * 2019-03-05 2022-05-26 Sichuan Gowell Pharmaceutical Co., Ltd. Fatty acid composition and application thereof
CN113368118B (zh) * 2021-07-21 2022-09-23 中国药科大学 磷脂酰胆碱在制备治疗溃疡性结肠炎的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3022136C2 (de) * 1980-06-13 1986-07-17 A. Nattermann & Cie GmbH, 5000 Köln Verfahren zum Abfüllen von Phospholipide enthaltenden pharmazeutischen Massen in Hartkapseln
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
IT1243981B (it) * 1990-10-01 1994-06-28 Fidia Spa Composizioni per il trattamento della pelle contenenti derivati della b-fosfatidilcolina
US5453523A (en) * 1993-06-16 1995-09-26 Emulsion Technology, Inc. Process for obtaining highly purified phosphatidylcholine
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DK1105141T3 (da) * 1998-08-06 2004-03-08 Wolfgang Stremmel Phosphatidylcholin som et medikament med slimhindebeskyttende virkning
PT2185158E (pt) * 2007-07-31 2014-03-27 Pat Gmbh Utilização de fosfatidilcolina para tratar colite ulcerosa dependente de esteróides e refractária a esteróides
CN102633832B (zh) * 2011-02-09 2015-07-22 北京绿色金可生物技术股份有限公司 一种制备高纯度磷脂酰胆碱的方法

Also Published As

Publication number Publication date
CA2907401A1 (en) 2014-10-02
EP2978416A1 (en) 2016-02-03
JP2016516087A (ja) 2016-06-02
IL241019A0 (en) 2015-11-30
PE20160037A1 (es) 2016-02-04
CN105377247A (zh) 2016-03-02
MD20150089A2 (ru) 2016-03-31
AU2014243102B2 (en) 2018-04-26
MX2015013511A (es) 2016-06-28
HK1217089A1 (zh) 2016-12-23
BR112015023849A2 (pt) 2017-07-18
US20160045523A1 (en) 2016-02-18
PT2978416T (pt) 2016-12-09
HUE030707T2 (en) 2017-05-29
EA029514B1 (ru) 2018-04-30
UA115585C2 (uk) 2017-11-27
AU2014243102A1 (en) 2015-09-17
CL2015002832A1 (es) 2016-03-11
ZA201507910B (en) 2017-04-26
EP2978416B1 (en) 2016-10-26
DK2978416T3 (en) 2016-12-19
LT2978416T (lt) 2016-12-12
CN105377247B (zh) 2019-04-26
WO2014154683A1 (en) 2014-10-02
ES2605650T3 (es) 2017-03-15
PH12015502199A1 (en) 2016-01-25
SG11201507777TA (en) 2015-10-29
PL2978416T3 (pl) 2017-03-31
KR20150132841A (ko) 2015-11-26
JP6262843B2 (ja) 2018-01-17

Similar Documents

Publication Publication Date Title
EA201591510A1 (ru) Фармацевтическая препаративная форма, содержащая фосфатидилхолин, применяемая для лечения язвенного колита
CL2019003105A1 (es) Lípidos extraídos de plantas que comprenden ácidos grasos poliinsaturados de cadena larga. (divisional solicitud 201601560)
IN2014MN02652A (ru)
SV2014004850A (es) Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1
IN2014MN02658A (ru)
IN2014MN02657A (ru)
AR088983A1 (es) Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
NZ739760A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
BR112013003772A2 (pt) composições de compostos modificadores de resposta imunológica lipidadas, formulações e métodos
NZ596228A (en) Compositions and methods for the treatment of inflammation
MX2015011074A (es) Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
UY32423A (es) Derivados de azaspiranil-alquilcarbamatos de 5 eslabones, su preparacion y su aplicacion en terapeutica
MY198214A (en) Fatty acid composition and use thereof
CU20170007A7 (es) Compuestos de imidazopiridazina
MX2017003237A (es) Metodo para producir esteres de astaxantina.
UY37856A (es) Mezclas inhibidoras de protoporfirinógeno oxidasas
CO2017001088A2 (es) Mezcla de ácidos grasos y palmitoiletanolamida para su uso en el tratamiento de patologías inflamatorias y alérgicas
ECSP15022442A (es) Producto de comicronización que comprende acetato de ulipristal
WO2014165190A3 (en) Compositions comprising docosapentaenoic acid and methods of use
AR107419A1 (es) Proceso para la preparación de ácidos 4-alcoxi-3-acetoxipicolínicos
MX2021001790A (es) Composiciones solidas de trigliceridos y usos de estas.
AR099070A1 (es) Ácido (s)- 3-metil-abscísico y ésteres del mismo
MX2015016679A (es) Formulaciones de agomelatina que comprenden agomelatina en forma de cocristales.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU